Hedge Fund - Sabby Capital

Hal Mintz's Sabby Capital disclosed a 1.5 million share position in Alliqua Biomedical Inc. (ALQA) last week. Sabby Capital held 665 thousand shares of ALQA at the end of 2015.

Hal Mintz's Sabby Capital has revealed a new position in Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) through a 13G filing with the SEC.

The HFRX Absolute Return Index, which measures the overall returns of the hedge fund industry, posted a negative return of 0.09% in 2015, which compares with a negative return of 0.73% delivered by the...

Sabby Management is a New Jersey-based activist hedge fund launched by Hal Mintz in June 2011.

According to a 13G form filed with the Securities and Exchange Commission, Hal Mintz’s Sabby Management has acquired a new passive stake in OncoSec Medical Incorporated (NASDAQ:ONCS).

Hal Mintz's Sabby Capital has initiated a passive stake in Superconductor Technologies, Inc. (NASDAQ:SCON) according to a schedule 13G form filed with the SEC.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) spiked nearly 18% during Tuesday's intraday trading and hit a 52-week high of $46.48.

Two of our tracked funds have recently revealed in filings with the SEC that they’ve taken large new passive positions in a couple of stocks.

We have a trifecta of recent hedge fund buying activity for you to digest, featuring three different funds and three different stocks.